SOURCE: Aethlon Medical

Aethlon Medical

December 08, 2010 09:15 ET

California Equity Research Initiates Coverage of Aethlon Medical

SAN DIEGO, CA--(Marketwire - December 8, 2010) - California Equity Research initiated coverage today of Aethlon Medical (OTCBB: AEMD).

Director of research Bud Leedom highlighted these themes in the initiation report:

  • Aethlon Medical is a leading player in blood filtration systems under development to treat infectious disease, cancer and in biodefense.
  • Aethlon has begun enrollment of its Hepatitis C clinical trial in India using Hemopurifier.
  • Hemopurifier is undergoing in vitro testing in five cancer indications focused on reducing exosome levels.
  • Aethlon has reestablished its biodefense program and is seeking government grants.
  • Aethlon shares could reach $0.95 over the next 12-24 months based on current catalysts.

The 26-page research report contains estimates and growth assumptions as Hemopurifier moves from the clinic to commercialization, and is available at

About California Equity Research, LLC

California Equity Research (CER) is an independent equity research firm headquartered in San Diego, California. Our intimate knowledge of companies based in California, particularly Southern California, allows our research team to uncover emerging opportunities well ahead of Wall Street. For more information, please visit


The securities discussed in California Equity Research equity research reports may be unsuitable for certain investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider this report as only a single factor in making their investment decisions and should not rely solely on this report in evaluating whether or not to buy or sell the securities of the subject company.

Regulation Analyst Certification ("Reg. AC")

All of the views expressed in this research report accurately reflect the research analyst's personal views about any and all of the subject securities or issuers. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the research analyst in the subject company of this research report.

Contact Information

  • For media inquiries, please contact:
    Bud Leedom
    Email Contact